‘Infarma’ Heads to BIOPROM: Innovative Pharmacology Takes Center Stage at Gelendzhik Forum

The innovative development of Russian pharmaceuticals, intellectual property protection, and state support measures for the industry will be key discussion topics at the session ‘Pharma: New Aspects of International Cooperation’ during the BIOPROM 2025 international forum in Gelendzhik held on October 6-7. Details were shared by Vadim Kukava, Executive Director of the Pharmaceutical Innovations Association (‘Infarma’) and one of the session organizers. A regular BIOPROM participant, Infarma unites major drug manufacturers ranked among the global top 20, all actively investing in R&D.

As Kukava noted, a primary goal of innovative drug development is to extend healthy lifespans and improve wellbeing, particularly for aging populations, a critical priority amid Russia’s demographic shifts and rising median age.

International collaboration remains vital: "Despite geopolitical challenges," stressed Infarma’s Executive Director, "foreign partners continue localizing production and investing in research, ensuring access to over 50% of high-tech medications by value."

Kukava emphasized BIOPROM’s unique advantage as a platform for direct dialogue among top experts, regulators, manufacturers, and researchers. Large-scale discussions involving businesses will yield concrete solutions to elevate Russia’s pharmaсeutical industry to a whole new level.